A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010).

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

Highlands Ranch Hospital
University of Colorado Hospital

Study ID

Protocol Number: 19-2721

More information available at ClinicalTrials.gov: NCT04199104

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers